Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.19.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Operating Costs and Expenses:        
General and administrative $ 1,044 $ 1,431 $ 2,199 $ 3,051
Research and development 2,594 3,572 5,012 6,942
Total Operating Costs and Expenses 3,638 5,003 7,211 9,993
Loss from Operations (3,638) (5,003) (7,211) (9,993)
Other Income :        
Change in fair value of warrant liability 0 783 0 3,438
Interest income 80 6 125 15
Total Other Income 80 789 125 3,453
Net Loss (3,558) (4,214) (7,086) (6,540)
Net Loss Attributable to Non-controlling Interest 27 17 43 26
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (3,531) (4,197) (7,043) (6,514)
Net Loss Attributable to Common Stockholders $ (3,709) $ (4,258) $ (7,680) $ (6,634)
Net Loss Per Share - Basic and Dilutive $ (0.23) $ (1.16) $ (0.48) $ (1.80)
Weighted average number of shares outstanding during the period - Basic and Dilutive 16,465,314 3,683,383 16,063,283 3,678,389
Series A Preferred Stock [Member]        
Other Income :        
Preferred Stock Dividends, Income Statement Impact $ (61) $ (61) $ (122) $ (120)
Series B Preferred Stock [Member]        
Other Income :        
Preferred Stock Dividends, Income Statement Impact $ (117) $ 0 $ (515) $ 0